BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35343466)

  • 1. Multiple Meningiomas as a Criterion for the Diagnosis of Neurofibromatosis Type 2 and Other Tumor Predisposition Syndromes.
    Hannan CJ; Hammerbeck-Ward C; Pathmanaban ON; Smith MJ; Rutherford SA; Lloyd SK; Mackenzie Freeman SR; Wallace AJ; King AT; Richard Evans DG
    Neurosurgery; 2022 Jun; 90(6):793-799. PubMed ID: 35343466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
    Louvrier C; Pasmant E; Briand-Suleau A; Cohen J; Nitschké P; Nectoux J; Orhant L; Zordan C; Goizet C; Goutagny S; Lallemand D; Vidaud M; Vidaud D; Kalamarides M; Parfait B
    Neuro Oncol; 2018 Jun; 20(7):917-929. PubMed ID: 29409008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article.
    Holman MA; Schmitt WR; Carlson ML; Driscoll CL; Beatty CW; Link MJ
    J Neurosurg Pediatr; 2013 Oct; 12(4):317-24. PubMed ID: 23909617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
    Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
    Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
    Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
    Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults.
    Pathmanaban ON; Sadler KV; Kamaly-Asl ID; King AT; Rutherford SA; Hammerbeck-Ward C; McCabe MG; Kilday JP; Beetz C; Poplawski NK; Evans DG; Smith MJ
    JAMA Neurol; 2017 Sep; 74(9):1123-1129. PubMed ID: 28759666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic and genotypic overlap between mosaic NF2 and schwannomatosis in patients with multiple non-intradermal schwannomas.
    Kehrer-Sawatzki H; Kluwe L; Friedrich RE; Summerer A; Schäfer E; Wahlländer U; Matthies C; Gugel I; Farschtschi S; Hagel C; Cooper DN; Mautner VF
    Hum Genet; 2018 Jul; 137(6-7):543-552. PubMed ID: 30006736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cases of Mixed Schwannoma-Meningioma With and Without Neurofibromatosis 2 with Emphasis on Tumorigenesis.
    Rajeswarie RT; Mallik D; Rudrappa S; Gopal S
    Int J Surg Pathol; 2024 May; 32(3):511-514. PubMed ID: 37487199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Segmental neurofibromatosis type 2: discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb.
    Castellanos E; Bielsa I; Carrato C; Rosas I; Solanes A; Hostalot C; Amilibia E; Prades J; Roca-Ribas F; Lázaro C; Blanco I; Serra E;
    BMC Med Genomics; 2015 Jan; 8():2. PubMed ID: 25739810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri.
    van den Munckhof P; Christiaans I; Kenter SB; Baas F; Hulsebos TJ
    Neurogenetics; 2012 Feb; 13(1):1-7. PubMed ID: 22038540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
    Lu-Emerson C; Plotkin SR
    Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
    Ruggieri M; Praticò AD; Evans DG
    Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unilateral vestibular schwannoma and meningiomas in a patient with PIK3CA-related segmental overgrowth: Co-occurrence of mosaicism for 2 rare disorders.
    Mills JR; Moyer AM; Kipp BR; Poplawski AB; Messiaen LM; Babovic-Vuksanovic D
    Clin Genet; 2018 Jan; 93(1):187-190. PubMed ID: 28737257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis.
    Smith MJ; Kulkarni A; Rustad C; Bowers NL; Wallace AJ; Holder SE; Heiberg A; Ramsden RT; Evans DG
    Am J Med Genet A; 2012 Jan; 158A(1):215-9. PubMed ID: 22105938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients.
    Aboukais R; Baroncini M; Zairi F; Bonne NX; Schapira S; Vincent C; Lejeune JP
    Acta Neurochir (Wien); 2013 May; 155(5):771-7. PubMed ID: 23381342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
    Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
    Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of clinical diagnostic criteria for neurofibromatosis 2.
    Baser ME; Friedman JM; Wallace AJ; Ramsden RT; Joe H; Evans DG
    Neurology; 2002 Dec; 59(11):1759-65. PubMed ID: 12473765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas.
    Antinheimo J; Sankila R; Carpén O; Pukkala E; Sainio M; Jääskeläinen J
    Neurology; 2000 Jan; 54(1):71-6. PubMed ID: 10636128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the CNS manifestations of neurofibromatosis type 2.
    Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
    Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.